Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

被引:237
作者
Geerlings, Suzanne [1 ]
Fonseca, Vivian [2 ]
Castro-Diaz, David [3 ]
List, James [4 ]
Parikh, Shamik [5 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun, Amsterdam CINIMA, NL-1105 AZ Amsterdam, Netherlands
[2] Tulane Univ, Hlth Sci Ctr, Endocrinol Sect, New Orleans, LA 70112 USA
[3] Univ Hosp Canary Isl, Tenerife 38320, Spain
[4] Bristol Myers Squibb Co, Global Dev Res & Dev, Princeton, NJ USA
[5] AstraZeneca, Global Med Affairs Diabet & Metab, Wilmington, DE USA
关键词
Type; 2; diabetes; Infections; Genital; Urinary; Glucosuria; SGLT2; INADEQUATE GLYCEMIC CONTROL; 2; SGLT2; INHIBITOR; ASYMPTOMATIC BACTERIURIA; DOUBLE-BLIND; RISK-FACTORS; ESCHERICHIA-COLI; DAPAGLIFLOZIN MONOTHERAPY; CANDIDA COLONIZATION; VAGINAL CANDIDIASIS; BODY-WEIGHT;
D O I
10.1016/j.diabres.2013.12.052
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated. (C) 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:373 / 381
页数:9
相关论文
共 52 条
[1]
Bailey C, 2011, 7 SCI SESS AM DIAB A
[2]
Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range [J].
Bailey, C. J. ;
Iqbal, N. ;
T'joen, C. ;
List, J. F. .
DIABETES OBESITY & METABOLISM, 2012, 14 (10) :951-959
[3]
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Pieters, Anne ;
Bastien, Arnaud ;
List, James F. .
LANCET, 2010, 375 (9733) :2223-2233
[4]
Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome [J].
Benfield, T. ;
Jensen, J. S. ;
Nordestgaard, B. G. .
DIABETOLOGIA, 2007, 50 (03) :549-554
[5]
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].
Bolinder, Jan ;
Ljunggren, Osten ;
Kullberg, Joel ;
Johansson, Lars ;
Wilding, John ;
Langkilde, Anna Maria ;
Sugg, Jennifer ;
Parikh, Shamik .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031
[6]
Carton J A, 1992, Eur J Med, V1, P281
[7]
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial [J].
Cefalu, William T. ;
Leiter, Lawrence A. ;
Yoon, Kun-Ho ;
Arias, Pablo ;
Niskanen, Leo ;
Xie, John ;
Balis, Dainius A. ;
Canovatchel, William ;
Meininger, Gary .
LANCET, 2013, 382 (9896) :941-950
[8]
Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes -: art. no. 1 [J].
de Leon, EM ;
Jacober, SJ ;
Sobel, JD ;
Foxman, B .
BMC INFECTIOUS DISEASES, 2002, 2 (1)
[9]
Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO
[10]
2-V